BMJ19h
THU0265 Identifying the links between iron deficiency and fatigue in adolescents and young adults with systemic lupus erythematosus
Background Between 80–90% of patients with systemic lupus erythematosus (SLE) report fatigue to be the single most troublesome and debilitating symptom of their illness. 1 Recent studies have found ...
BMJ15h
AB0132 AFIMETORAN (BMS-986256), AN EQUIPOTENT TLR7/8 ANTAGONIST, DEMONSTRATES STEROID-SPARING EFFECTS IN A LUPUS MOUSE MODEL
2 Biocon Bristol Myers Squibb Research Center, Discovery Biology, Bangalore, India 3 Bristol Myers Squibb, Medicinal Chemistry, Lawrenceville, United States of America 4 Bristol Myers Squibb, ...
BMJ1d
Joachim Robert Kalden: one of the founders of autoimmunity research and immunotherapy
Correspondence to Prof. Dr. Gerd R Burmester, Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany; gerd.burmester{at}charite.de Born in ...
BMJ11d
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis
Objective Innate lymphoid cells-2 (ILC2) were shown to be involved in the development of lung or hepatic fibrosis. We sought to explore the functional and phenotypic heterogeneity of ILC2 in skin ...
BMJ6d
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Correspondence to Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden D-01307, Germany; martin.aringer{at}uniklinikum-dresden.de; Dr ...
BMJ6d
Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications
Objective Autoantibodies against antigens carrying distinct post-translational modifications (PTMs), such as citrulline, homocitrulline or acetyllysine, are hallmarks of rheumatoid arthritis (RA). The ...
BMJ1d
POS0471 CONTINUOUSLY LOW MUSCLE MASS CONTRIBUTES TO WORSE PHYSICAL FUNCTION IN RHEUMATOID ARTHRITIS PATIENTS: A 5-YEAR FOLLOW-UP STUDY
Background: Rheumatoid arthritis (RA) is characterized with joint damage and physical dysfunction, leading to reducing quality of life. The causes of physical dysfunction in RA are multifactorial, ...
BMJ6d
Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7
Objectives To investigate the role of mechanical stress in cartilage ageing and identify the mechanistic association during osteoarthritis (OA) progression. Conclusions FBXW7 is a key factor in the ...
BMJ10d
Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis
Objectives To report the 10-year outcome of lupus nephritis (LN) treated with mycophenolate mofetil (MMF) or tacrolimus (TAC) induction in a randomised controlled trial. Methods Patients with active ...
BMJ9d
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
16 Department of Clinical Microbiology, Clinical Immunology, Umeå University, Umeå, Sweden 17 Department of Laboratory Medicine, Clinical Immunology, University Hospital of Orebro and Orebro ...
BMJ7d
Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis
Correspondence to Dr Ki-Jo Kim, Division of Rheumatology, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, 93, Jungbu-daero, Paldal-gu, ...
BMJ11d
Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis
Background Juvenile idiopathic arthritis is one of the most prevalent chronic inflammatory diseases in children. Evidence suggests that early effective treatment minimises the burden of disease during ...